General dosing: Infants, Children, and Adolescents:
Mild to moderate infection: Oral: 25 to 50 mg/kg/day in divided doses every 6 hours; maximum daily dose: 2,000 mg/day (Ref).
Anthrax (penicillin-susceptible strains) (alternative agent) (Ref): Infants, Children, and Adolescents:
Postexposure prophylaxis, exposure to aerosolized spores: Oral: 50 to 75 mg/kg/day in divided doses every 6 to 8 hours for 60 days.
Cutaneous, without systemic involvement: Oral: 50 to 75 mg/kg/day in divided doses every 6 to 8 hours. Duration: 7 to 10 days for naturally acquired infection, up to 60 days for biological weapon-related event/exposure to aerosolized spore.
Systemic, oral step-down therapy: Oral: 50 to 75 mg/kg/day in divided doses every 6 to 8 hours to complete 60-day course; should be used as a component of combination therapy.
Fusospirochetosis (Vincent infection), mild to moderately severe infections: Children ≥12 years and Adolescents: Oral: 250 to 500 mg every 6 to 8 hours.
Pneumonia, community-acquired; Group A Streptococcus , mild infection or step-down therapy:
Infants, Children, and Adolescents: Oral: 50 to 75 mg/kg/day in divided doses 4 times daily (Ref); Note: Usual adult maximum daily dose is 2,000 mg/day.
Pneumococcal infection prophylaxis for anatomic or functional asplenia (eg, sickle cell disease [SCD]) (Ref):
Infants (as soon as SCD diagnosed or asplenic) and Children <3 years: Oral: 125 mg twice daily.
Children ≥3 years: Oral: 250 mg twice daily.
Note: Current guidelines recommend discontinuation of prophylaxis at 5 years of age unless the patient has experienced invasive pneumococcal infection or splenectomy; data regarding when to discontinue are limited and practice varies; decision should be made on a case-by-case basis (Ref).
Pneumococcal infection prophylaxis, patients post-hematopoietic cell transplant with chronic graft-versus-host disease or low IgG levels (Ref): Note: Use only in areas where incidence of penicillin-resistant Streptococcus pneumoniae is low.
Infants ≥2 months and Children ≤3 years: Oral: 125 mg twice daily.
Children >3 years: Oral: 250 mg twice daily.
Adolescents: Oral: 250 to 500 mg twice daily or 500 to 1,000 mg once daily.
Streptococcus, group A:
Pharyngitis/tonsillitis: Limited data available in <12 years of age:
Children ≤27 kg: Oral: 250 mg every 8 to 12 hours for 10 days (Ref).
Children >27 kg and Adolescents: Oral: 500 mg every 8 to 12 hours for 10 days (Ref).
Rheumatic fever, secondary prevention: Limited data available in <12 years of age: Note: IM benzathine penicillin G is preferred, except in patients who are at elevated risk of death from cardiovascular compromise with IM penicillin (eg, severe valvular disease, ventricular ejection fraction <50%, NYHA class III/IV symptoms) (Ref).
Children and Adolescents: Oral: 250 mg twice daily. Duration depends on risk factors including number of previous attacks, risk of exposure to Group A streptococcal infections, age, and presence of valvular disease (Ref).
Chronic carriage: Limited data available: Note: Most individuals with chronic carriage do not require antibiotic treatment (Ref).
Children and Adolescents: Oral: 50 mg/kg/day in 4 divided doses for 10 days; maximum dose: 500 mg/dose; give in combination with oral rifampin for the last 4 days of therapy (Ref).
Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; excretion is prolonged in patients with kidney impairment.
There are no dosage adjustments provided in the manufacturer's labeling.
(For additional information see "Penicillin V potassium (oral): Drug information")
Actinomycosis (off-label use):
Note: For initial therapy of mild infection or step-down therapy following parenteral treatment of severe infection.
Oral: 500 mg to 1 g every 6 hours (Ref). Optimal duration is uncertain; some experts suggest total durations of 2 to 6 months for mild infection and 6 to 12 months for severe or extensive infection (Ref).
Anthrax (alternative agent for penicillin-susceptible strains) (off-label use):
Note: Consult public health officials for event-specific recommendations. A high index of suspicion for emergent beta-lactam resistance during therapy is warranted (Ref).
Inhalational exposure (postexposure prophylaxis): Oral: 500 mg every 6 hours (Ref); duration depends on anthrax vaccine status and series completion, age, immune status, and pregnancy/breastfeeding status; for those who have not previously received anthrax vaccine, duration ranges from 42 to 60 days (Ref). Note: Anthrax vaccine should also be administered to exposed individuals (Ref).
Cutaneous, without systemic involvement, treatment: Oral: 500 mg every 6 hours; duration is 7 to 10 days after naturally acquired infection and 60 days following biological weapon–related event. Note: Patients with extensive edema or cutaneous lesions of the head or neck should be treated with a parenteral regimen recommended for systemic infection (Ref).
Diphtheria (adjunctive therapy with antitoxin) (off-label use):
Oral: 500 mg every 6 hours to complete a total treatment course of 14 days (Ref).
Meningococcal prophylaxis in patients with complement deficiency (eg, due to C5 inhibitor therapy) (off-label use): Limited data:
Oral: 500 mg twice daily in addition to meningococcal vaccination; for those taking a C5 inhibitor, administer meningococcal vaccination 2 weeks prior to initiation of C5 inhibitor therapy and give penicillin V potassium for the duration of C5 inhibitor therapy (Ref).
Pneumococcal prophylaxis in patients at high risk (off-label use):
Note: For select patients at high risk (eg, patients with functional or anatomic asplenia, sickle cell disease, allogeneic hematopoietic cell transplant recipients with chronic graft-vs-host disease or hypogammaglobulinemia) (Ref).
Oral: 250 to 500 mg twice daily; duration varies based on patient-specific factors (Ref).
Prosthetic joint infection, chronic suppression (off-label use):
Note: For infection caused by beta-hemolytic streptococci, penicillin-susceptible Enterococcus spp., or Cutibacterium spp. (following pathogen-specific IV therapy in patients undergoing 1-stage exchange or debridement with retention of prosthesis) (Ref).
Oral: 500 mg 2 to 4 times daily (IDSA [Osmon 2013]); duration depends on patient-specific factors (Ref).
Rat bite fever, uncomplicated infection (off-label use):
Oral: 500 mg every 6 hours following parenteral therapy to complete a total treatment course of 14 days (Ref).
Skin and soft tissue infection:
Cellulitis, long-term suppression of recurrent infection (off-label use): Note: For patients with recurrent presumptive beta-hemolytic streptococcal cellulitis at the same anatomical site despite addressing predisposing factors (Ref).
Oral: 250 to 500 mg twice daily after completion of treatment (Ref).
Erysipelas, treatment of mild infection or step-down therapy after initial parenteral therapy: Oral: 500 mg every 6 hours; total duration is 5 days, with extension to 14 days for slow response, severe infection, or immunosuppression (Ref).
Erysipeloid (localized cutaneous Erysipelothrix rhusiopathiae infection), treatment (off-label use): Oral: 500 mg every 6 hours for 5 to 10 days (Ref).
Streptococcus, group A:
Pharyngitis: Oral: 500 mg 2 to 3 times daily for 10 days (Ref); 250 mg 4 times daily may also be given, but clinical efficacy with less frequent dosing appears comparable (Ref).
Secondary prophylaxis in patients with rheumatic fever (prevention of recurrent attacks) (alternative agent): Note: IM benzathine penicillin G is preferred, except in patients who are at elevated risk of death from cardiovascular compromise with IM penicillin (eg, severe valvular disease, ventricular ejection fraction <50%, NYHA class III/IV symptoms) (Ref).
Oral: 250 mg twice daily. Duration depends on risk factors, age, and presence of valvular disease (Ref).
Chronic carriage (off-label use): Note: Most individuals with chronic carriage do not require antimicrobial treatment (Ref).
Oral: 500 mg 4 times daily for 10 days; add rifampin for the last 4 days of therapy (Ref).
Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
There are no dosage adjustments provided in manufacturer's labeling. Use with caution; excretion is prolonged in patients with renal impairment.
There are no dosage adjustments provided in manufacturer's labeling.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
>10%: Gastrointestinal: Melanoglossia, mild diarrhea, nausea, oral candidiasis, vomiting
<1%: Acute interstitial nephritis, anaphylaxis, convulsions, exfoliative dermatitis, fever, hemolytic anemia, hypersensitivity reaction, positive direct Coombs test, serum-sickness like reaction
Hypersensitivity to penicillin or any component of the formulation.
Concerns related to adverse effects:
• Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity or history of sensitivity to multiple allergens.). Use with caution in asthmatic patients. If a serious reaction occurs, treatment with supportive care measures and airway protection should be instituted immediately.
• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.
Disease-related concerns:
• Renal impairment: Use with caution in patients with severe renal impairment.
• Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.
Dosage form specific issues:
• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.
Other warnings/precautions:
• Prolonged use: Extended duration of therapy or use associated with high serum concentrations (eg, in renal insufficiency) may be associated with an increased risk for some adverse reactions (neutropenia, hemolytic anemia, serum sickness).
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution Reconstituted, Oral:
Generic: 125 mg/5 mL (100 mL, 200 mL); 250 mg/5 mL (100 mL, 200 mL)
Tablet, Oral:
Generic: 250 mg, 500 mg
Yes
Solution (reconstituted) (Penicillin V Potassium Oral)
125 mg/5 mL (per mL): $0.10
250 mg/5 mL (per mL): $0.11
Tablets (Penicillin V Potassium Oral)
250 mg (per each): $0.46 - $1.19
500 mg (per each): $0.78 - $2.02
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Tablet, Oral:
Generic: 300 mg
0.7 mEq of potassium/250 mg penicillin V; 250 mg = 400,000 units of penicillin
Oral: To enhance absorption, administer with water on an empty stomach.
Oral: Administer around-the-clock to promote less variation in peak and trough serum levels. Take on an empty stomach 1 hour before or 2 hours after meals, to enhance absorption.
Powder for oral solution: Store dry powder at 20°C to 25°C (68°F to 77°F). Reconstituted oral solution should be stored in refrigerator. Discard unused solution after 14 days (consult manufacturer labeling for specific recommendations).
Tablet: Store at 20°C to 25°C (68°F to 77°F).
Treatment of mild to moderately severe susceptible bacterial infections involving the upper respiratory tract and skin and soft tissues, including pneumococcal infections, staphylococcal infections, streptococcal infections (without bacteremia); treatment of fusospirochetosis; prophylaxis of rheumatic fever and/or chorea (All indications: FDA approved in ages ≥12 years and adults); has also been used for prophylaxis of invasive pneumococcal infections in high-risk patients, treatment of community-acquired cutaneous anthrax, and treatment of community-acquired pneumonia caused by group A Streptococcus.
Penicillin may be confused with penicillAMINE
Penicillin V potassium may be confused with penicillin G benzathine, penicillin G (parenteral/aqueous), penicillin G procaine
Substrate of OAT1/3
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program
Acemetacin: May increase the serum concentration of Penicillins. Risk C: Monitor therapy
Aminoglycosides: Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. Risk C: Monitor therapy
Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii. Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy. Risk D: Consider therapy modification
BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination
BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Risk C: Monitor therapy
Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid combination
Dichlorphenamide: Penicillins may enhance the hypokalemic effect of Dichlorphenamide. Risk C: Monitor therapy
Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics. Risk X: Avoid combination
Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). Risk X: Avoid combination
Guar Gum (Partially Hydrolyzed): May decrease the serum concentration of Penicillin V Potassium. Risk C: Monitor therapy
Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Risk C: Monitor therapy
Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Risk C: Monitor therapy
Methotrexate: Penicillins may increase the serum concentration of Methotrexate. Risk C: Monitor therapy
Mycophenolate: Antibiotics may decrease serum concentrations of the active metabolite(s) of Mycophenolate. Specifically, concentrations of mycophenolic acid (MPA) may be reduced. Risk C: Monitor therapy
Probenecid: May increase the serum concentration of Penicillins. Risk C: Monitor therapy
Sodium Benzoate: Penicillins may diminish the therapeutic effect of Sodium Benzoate. Risk C: Monitor therapy
Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider therapy modification
Tetracyclines: May diminish the therapeutic effect of Penicillins. Risk C: Monitor therapy
Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Avoid use of live attenuated typhoid vaccine (Ty21a) in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose. Risk D: Consider therapy modification
Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy
Food decreases drug absorption rate; decreases drug serum concentration. Management: Take on an empty stomach 1 hour before or 2 hours after meals around-the-clock to promote less variation in peak and trough serum levels.
Penicillin crosses the placenta (Heikkilä 1994).
Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of penicillin V may be altered in the second and third trimester (Heikkilä 1993).
Penicillin is widely used in pregnant patients. Based on available data, penicillin is generally considered compatible for use during pregnancy (Ailes 2016; Bookstaver 2015; Crider 2009; Damkier 2019; Dencker 2002; Heikkilä 1994; Heinonen 1977; Lamont 2014; Muanda 2017a; Muanda 2017b).
Penicillin is recommended for the management of syphilis during pregnancy. Penicillin V is not recommended for treatment; however, it may be used in the desensitization protocol so that the appropriate penicillin formulation may then be used (CDC [Workowski 2021]; Dallé 2018).
If treatment for the management of Bacillus anthracis is needed in pregnant patients, other agents are preferred (Meaney-Delman 2014).
With prolonged therapy, monitor renal and hematologic function periodically; observe for change in bowel frequency; monitor for signs of anaphylaxis during first dose.
Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.
Protein binding, plasma: 80%.
Bioavailability: Oral: 60% to 73% (Nathwani 1993).
Half-life elimination: Terminal: Oral: 30 minutes (Nathwani 1993); 62 ± 14 minutes (Lindberg 1987); 112 ± 47 minutes (Heikkilä 1993).
Excretion: Urine (as unchanged drug and metabolites).
Altered kidney function: Excretion is considerably delayed.
Pediatric: In neonates and young infants, excretion is considerably delayed.
Anti-infective considerations:
Parameters associated with efficacy:
Time dependent, associated with time free drug concentration (fT) > minimum inhibitory concentration (MIC), goal: ≥50% fT > MIC (bactericidal) (Craig 1996; Craig 1998).
Expected drug exposure in adults with normal renal function:
Cmax (peak):
500 mg every 6 hours, steady state: 4.9 to 6.3 mg/L (MacGregor 1997).
Postantibiotic effect: Minimal bacterial killing continues after penicillin concentration falls below the MIC of targeted pathogen and varies based on the organism:
Gram-positive cocci: 1.5 to 3.5 hours (Craig 1991; Garcia 1995; Zhanel 1991).
Gram-negative bacilli: 0 to 1.5 hours (Craig 1991; Zhanel 1991).
Do you want to add Medilib to your home screen?